Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
The DOI matches its Crossref record; 164 of the 164 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases (NDs) are currently incurable diseases that cause progressive degeneration of nerve cells. Many of the disease-causing proteins of NDs are “undruggable” for traditional small-molecule inhibitors (SMIs). None of the compounds that attenuated the amyloid-β (Aβ) accumulation process have entered clinical practice, and many phase III clinical trials of SMIs for Alzheimer’s disease (AD) have failed. In recent years, emerging targeted protein degradation (TPD) technologies such as proteolysis-targeting chimeras (PROTACs), lysosome-targeting chimaeras (LYTACs), and autophagy-targeting chimeras (AUTACs) with TPD-assistive technologies such as click-formed proteolysis-targeting chimeras (CLIPTACs) and deubiquitinase-targeting chimera (DUBTAC) have developed rapidly. In vitro and in vivo experiments have also confirmed that TPD technology can target the degradation of ND pathogenic proteins, bringing hope for the treatment of NDs. Herein, we review the latest TPD technologies, introduce their targets and technical characteristics, and discuss the emerging TPD technologies with potential in ND research, with the hope of providing a new perspective for the development of TPD technology in the NDs field.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These PROTACs target tau protein, phosphokinase GSK-3β, HDACs, BET proteins, and transthyretin (TTR)-Aβ interaction, exhibiting characteristics such as low dosage requirements, high efficacy, and high target selectivity.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [575]
In the citing paper
“The PROTACs exploit the UPS system to precisely target specific proteins, improving the accuracy and speed of protein degradation.575”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [575]
Citations
Cites
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.
Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., Ohsumi, Y., & Yoshimori, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.21.5720 · Cited by 6,605
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Breijyeh, Z., & Karaman, R. (2020) · Molecules · doi:10.3390/molecules25245789 · Cited by 2,789
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
MTOR: a pharmacologic target for autophagy regulation
Kim, Y. C., & Guan, K.-L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73939 · Cited by 2,126
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Research works printed but not linked: 2
- Citron B. A., 2015, Am. J. Neurodegener. Dis., 4, 40
- Bachstetter A. D., 2010, Aging Dis., 1, 199
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
“575 Various reviews 574,575 have consolidated information on PROTACs with potential applications in AD.”
BackgroundSelf-citationProtein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Proximity-Based Modalities for Biology and Medicine
Liu, X., & Ciulli, A. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00395 · Cited by 196
A bibliometric analysis of PROTAC from 2001 to 2021
Li, D., Yu, D., Li, Y., & Yang, R. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114838 · Cited by 134
Xie, S., Zhu, J., Li, J., Zhan, F., Yao, H., Xu, J., & Xu, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00736 · Cited by 117
Antiviral PROTACs: Opportunity borne with challenge
Liang, J., Wu, Y., Lan, K., Dong, C., Wu, S., Li, S., & Zhou, H. (2023) · Cell Insight · doi:10.1016/j.cellin.2023.100092 · Cited by 77
Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects
Chen, Y., Wang, Y., Wang, J., Zhou, Z., Cao, S., & Zhang, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01523 · Cited by 75
Self-citationSmall-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Hu, J., Zhang, D., Tian, K., Ren, C., Li, H., Lin, C., Huang, X., Liu, J., Mao, W., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115475 · Cited by 65
Self-citationMayuri, K., Sreeraman, S., Somala, C. S., Kushwah, R. B. S., Saravanan, K. M., Sundaram, V., & Anand, T. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0072 · Cited by 65
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates
Zhu, W., Zhang, W., Chen, J., Tong, Y., Xu, F., & Pang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01719 · Cited by 57
Medicinal chemistry strategies targeting PRMT5 for cancer therapy
Fu, S., Zheng, Q., Zhang, D., Lin, C., Ouyang, L., Zhang, J., & Chen, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114842 · Cited by 51
Self-citationStrategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges
Zhang, R., Wang, Y., Wu, A., Wang, J., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115658 · Cited by 51
Self-citationSmall molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives
Niu, Z., Lei, P., Wang, Y., Wang, J., Yang, J., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115326 · Cited by 44
Self-citationDesantis, J., Bazzacco, A., Eleuteri, M., Tuci, S., Bianconi, E., Macchiarulo, A., Mercorelli, B., Loregian, A., & Goracci, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116202 · Cited by 43
Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles
Chen, L., Mao, W., Ren, C., Li, J., & Zhang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01802 · Cited by 42
Self-citationXin, X., Wang, Y., Zhang, L., Zhang, D., Sha, L., Zhu, Z., Huang, X., Mao, W., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115102 · Cited by 38
Self-citationNew implications for prion diseases therapy and prophylaxis
Liu, F., Lü, W., & Liu, L. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1324702 · Cited by 35
Targeting glutaminase 1 (GLS1) by small molecules for anticancer therapeutics
Chen, Y., Tan, L., Gao, J., Lin, C., Wu, F., Li, Y., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115306 · Cited by 31
Self-citationRu, J., Wang, Y., Li, Z., Wang, J., Ren, C., & Zhang, J. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115800 · Cited by 29
Self-citationProtein modification in neurodegenerative diseases
Ramazi, S., Dadzadi, M., Darvazi, M., Seddigh, N., & Allahverdi, A. (2024) · MedComm · doi:10.1002/mco2.674 · Cited by 29
Yu, S., Shi, T., Li, C., Xie, C., Wang, F., & Liu, X. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c03102 · Cited by 26
Rational Proteolysis Targeting Chimera Design Driven by Molecular Modeling and Machine Learning
Tan, S., Chen, Z., Lu, R., Liu, H., & Yao, X. (2025) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70013 · Cited by 26
Recent advances in dual PROTACs degrader strategies for disease treatment
Liu, J., Liu, Y., Tang, J., Gong, Q., Yan, G., Fan, H., Zhang, X., & Pu, C. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116901 · Cited by 25
Banoo, R., Nuthakki, V. K., Wadje, B. N., Sharma, A., & Bharate, S. B. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116131 · Cited by 24
Zhou, Q., Wang, W., & Deng, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04838-0 · Cited by 21
Research progress of DDR1 inhibitors in the treatment of multiple human diseases
Liu, M., Zhang, J., Li, X., & Wang, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116291 · Cited by 20
Self-citationAdvancements in PROTAC-based therapies for neurodegenerative diseases
Kong, D., Meng, L., Lin, P., & Wu, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463310 · Cited by 19
The Role of Kinases in Neurodegenerative Diseases: From Pathogenesis to Treatment
Naim, A., Farooqui, A. M., Badruddeen, B., Khan, M. I., Akhtar, J., Ahmad, A., & Islam, A. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70156 · Cited by 18
Zhou, H., Gan, Y., Li, Y., Chen, X., Guo, Y., & Wang, R. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01721 · Cited by 16
Contemporary trends in targeted protein degradation for neurodegenerative diseases
Kumar, G., Thakur, V., Sardana, S., Tiwari, V. K., Sharma, D., & Kumar, A. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118110 · Cited by 15
Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders
Nguyen, T. T., Nguyen‐Thi, P., Nguyen, T. H. A., Ho, T.-T., An, T. N. M., Toi, V. V., & Giau, V. V. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00654-1 · Cited by 15
Hydrophobic tagging: A promising paradigm for targeted protein degradation
Xin, L., Wang, H., Yang, M., Guo, Z., Zhu, M., Moore, T. W., Dong, C., & Zhou, H. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100295 · Cited by 14
Development and therapeutic perspectives of CXCR4 antagonists for disease therapy
Yang, J., Tian, E., Chen, L., Liu, Z., Ren, Y., Mao, W., Zhang, Y., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116594 · Cited by 13
Self-citationGe, R., Chen, M., Li, Q., Liu, M., Zhou, J., & Xie, S. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01538-2 · Cited by 13
Voicu, V. A., Tătaru, C. P., Toader, C., Covache-Busuioc, R.-A., Glavan, L.-A., Bratu, B.-G., Costin, H. P., Corlatescu, A.-D., & Ciurea, A. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613006 · Cited by 13
Tippett, D. C., Neophytou, K., Tao, Y., Gallegos, J., Morrow, C. B., Onyike, C. U., & Tsapkini, K. (2024) · Journal of Central Nervous System Disease · doi:10.1177/11795735241258435 · Cited by 12
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
Li, X., Li, J., Sun, Y., Yao, T., Lu, Y., Liu, S., Li, H., Shi, Y., Chen, L., Zhao, Y., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115876 · Cited by 11
Oxidation-labile linkers for controlled drug delivery
Carneiro, A., Santana, L., & Matos, M. J. (2023) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2023.129264 · Cited by 9
Singh, D. D., Yadav, D. K., & Shin, D. (2025) · Antioxidants · doi:10.3390/antiox14121426 · Cited by 10
Fan, D., Liu, P., Li, Z., He, X., Zhang, L., Jiang, W., Ang, W., & Yang, T. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107565 · Cited by 9
FibrilPaint to determine the length of Tau amyloids in fluids
Pedrola, J. A., Dekker, F. A., Garfagnini, T., Mayer, G., Koopman, M. B., Bergmeijer, M., Heesink, G., Rots, I., Claessens, M. M. A. E., Förster, F. G., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2502847122 · Cited by 9
Molecular features defining the efficiency of bioPROTACs
Winkelvoß, D., Vukovic, D., Hänny, A.-C., Riermeier, L., Udovcic, A., Kolibius, J., Honegger, A., Mittl, P. R. E., Michel, E., Hansen, S., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08352-w · Cited by 8
Proximity-Induced Pharmacology for Amyloid-Related Diseases
Bertran‐Mostazo, A., Putriūtė, G., Álvarez-Berbel, I., Busquets, M. A., Galdeano, C., Espargaró, A., & Sabaté, R. (2024) · Cells · doi:10.3390/cells13050449 · Cited by 8
mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation
Xue, X., Zhang, C., Li, X., Wang, J., Zhang, H., Feng, Y., Xu, N., Li, H., Tan, C., Jiang, Y., et al. (2024) · MedComm · doi:10.1002/mco2.478 · Cited by 9
Self-citationMisfolded Proteins and Cognitive Decline: Mechanistic Insights into Neurodegenerative Disorders
Duranti, E., & Villa, C. (2026) · Neurology International · doi:10.3390/neurolint18030048 · Cited by 7
Xiao, L., Mei, Z., Chen, J., Zhao, K., Zhang, H., Sharma, S., Liao, A., & Liu, C. (2025) · American Journal of Reproductive Immunology · doi:10.1111/aji.70066 · Cited by 7
Luo, W., Gu, Y., Fu, S., Wang, J., Zhang, J., & Wang, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115762 · Cited by 7
Self-citationDu, B., Ru, J., Zhan, Z., Lin, C., Liu, Y., Mao, W., & Zhang, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116286 · Cited by 7
Self-citationShehzadi, K., Ran, Y., Kalsoom, I., Dong, J., Gao, P., Irfan, M., Yu, M., Meng, Z., & Liang, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02065 · Cited by 6
Qian, C., Li, X., Zhang, J., & Wang, Y. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01064 · Cited by 5
Self-citationFeng, X., & Wang, H. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00484 · Cited by 5
Heparan Sulfate-Based Neoproteoglycan for Targeted Lysosomal Degradation of Amyloid-β
Vishweshwara, S. S., Anand, S., Bhoge, P. R., Mahida, V., Chandra, A., Saladi, S. V., & Kikkeri, R. V. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00845 · Cited by 5
Wang, Y., Zheng, J., Long, Y., Wu, W., & Zhu, Y. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115989 · Cited by 5
Self-citationBRD4 as an emerging epigenetic therapeutic target for inflammatory bowel disease
Ma, Z., Bolinger, A. A., Pinchuk, I. V., Tian, B., & Zhou, J. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.10.008 · Cited by 5
Hui, S., Long, Y., Zhu, L., Shi, W., Zheng, Q., & Liang, L. (2025) · Brain Research · doi:10.1016/j.brainres.2025.150067 · Cited by 5
Self-citationPROTACs for central nervous system disorders: challenges and opportunities
Zheng, N., Shao, J., Xiong, B., Wei, Y., Wang, X., Zhou, Y., Song, Z., Zhang, A., Xu, C., Zhao, Q., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118703 · Cited by 4
Khan, M. S., Zafar, I., Noman, M., Yang, G., Kang, K. S., & Bopassa, J. C. (2026) · Cells · doi:10.3390/cells15110962 · Cited by 5
The Effects of Nanotechnology and Theranostic on Neurodegenerative Diseases
Otero, M. M., Sneed, K., & Pathak, Y. V. (2024) · Chemical & Pharmaceutical Research · doi:10.33425/2689-1050.1058 · Cited by 4
Abdi, H., Vilana, S. G., Sánchez‐Molina, D., & Rahimi‐Movaghar, V. (2025) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-025-10409-2 · Cited by 4
Autophagy degradation: a promising dimension in drug discovery for neurodegenerative diseases
Liu, S., Cai, C., Zhu, H.-P., Li, X., & Han, B. (2024) · Future Medicinal Chemistry · doi:10.1080/17568919.2024.2431477 · Cited by 4
Targeted Protein Degradation and Delivery Strategies in the Context of Neurological Disorders
Lu, H., Yang, Z., Kayumov, M., Wang, Y., Tang, F., Wang, X., Xia, T., Lei, T., Tong, F., & Gao, H. (2026) · ACS Nano · doi:10.1021/acsnano.6c04420 · Cited by 3
Self-citationCodony, S., Jora, B., Santos-Caballero, M., Qiu, Q., Calvó‐Tusell, C., Escriche, C., Turcu, A. L., Prischi, F., Bartra, C., Val, C., et al. (2025) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2025.2574990 · Cited by 2
Antibacterial PROTACs: the road ahead for next-generation antibiotics?
Milelli, A., Raimondi, S., Asgharpour, S., Docquier, J., & Spyrakis, F. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104656 · Cited by 2
Su, G., Wang, Y., & Yao, L. (2026) · Pharmaceuticals · doi:10.3390/ph19070988 · Cited by 2
Self-citationFibrilpaint20 directs the ubiquitin–proteasome system to Tau amyloid fibrilsPreprint
Dekker, F. A., Pedrola, J. A., van Weert, E., den Breejen, A., Peters, L., Poza-Rodriguez, A., Mayer, G., Singh, S., Vertegaal, A. C. O., Friedler, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.27.609886 · Cited by 2
Molecular Degraders: A Comprehensive Review of Small Molecule Induced Protein Degradation Strategies
Sindhwani, D., Arora, K., kumar, P., Verma, P. K., & Bhosale, V. V. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037355750250526052851 · Cited by 1
Novás, M., Matos, M. J., & Chai, C. L. L. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2646603 · Cited by 1
Design and delivery of targeting chimeras therapeutics in managing central nervous system disorders
Liu, S., Xu, W., Wang, M., Mao, Z., Zhou, J., Gu, X., Han, G., & Ding, Y. (2026) · Targetome · doi:10.48130/targetome-0026-0028 · Cited by 1
Chemical Approaches for Array Based Detection of Amyloids
Simon, P. M., Xu, Y., & Kaur, A. (2025) · Advanced Sensor Research · doi:10.1002/adsr.202500108 · Cited by 1
Guduru, K. K., Gundawar, R., Eranti, B., Turaga, K., Sahista Anjum, S., Tadimarri, P., Pujari, H. P., Mahasool, W. T., & Arigela, P. P. (2025) · Drug Metabolism and Bioanalysis · doi:10.2174/0118723128397400250910222116 · Cited by 1
Proteolysis targeting chimeras (PROTAC) for targeting Alzheimer’s disease
Singh, A., Rani, A., & Mazumder, A. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00276-3 · Cited by 1
Ren, C., Liu, J., Pu, S., Zhou, H., Li, J., & Zhang, J. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0035 · Cited by 1
Self-citationWITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J.-Z. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
RetractedDong, Y. J., & Lu, J. (2024) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0039
Discovery and evaluation of HW161023 as a potent and orally active AAK1 inhibitor
Li, J., Liu, L., Liu, L., Jiang, W., Jia, Y., Yang, J., Li, L., Zhang, X., Su, J., & Kaushik, S. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130012
Promising Directions for the Development of Chemotherapy for Viral Infections
Loginova, S. Y., Borisevich, S. V., Николаевна, Щ. В., Savenko, S. V., & Rubtsov, V. V. (2025) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2025-70-3-4-69-83
Edo, H., Itano, R., & Umezawa, M. (2025) · Environmental Science and Pollution Research · doi:10.1007/s11356-025-37141-5
Design, synthesis, and evaluation of petrosiol E derivatives on neuronal progenitors differentiation
Liu, Y., Pan, R., Xie, X., Liu, J., & Du, Y. (2025) · Tetrahedron · doi:10.1016/j.tet.2025.135060
Zuo, W., Huang, X., Peng, C., Han, B., & Zhao, Q. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2605014
Podboršek, L. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Črešnar, T. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Singh, S., Singh, P. B. R. P., P, V. M., Vijaivasudev, M. J., Kumar, R., & Malik, I. (2026) · NAR Molecular Medicine · doi:10.1093/narmme/ugaf044
RNA-targeting antisense therapies in neurodegenerative diseases
Valjus, I. (2023) · Tampere University Institutional Repository (Tampere University)
Ghosh, P., Dhir, R., Sharma, D., & Asati, V. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11567-6 · Cited by 1
Small-molecule-mediated RNA targeting: emerging strategies and therapeutic potential of RiboTAC
Zhou, W., 金锦梅, Wu, Y., 陈红专, Zhang, W., & Luan, X. (2026) · Targetome · doi:10.48130/targetome-0026-0023
Leveraging Supramolecular Polymers to Induce the Targeted Protein Degradation of α-SynucleinPreprint
Swetman, W. S., Mondal, M., Davis, A. M., Rangachari, V., & Clemons, T. D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.20.739556
Hailu, G. S., Fabbrizi, E., Mancini, A., Fiorentino, F., Mai, A., & Rotili, D. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104769
Anbaraki, A., Shooshtari, M. Y. F., Dindar, Z., Irandoust, M., Mohammad-Zaheri, M., Mousavi-Jarrahi, Z., Saboury, A. A., & Seyedarabi, A. (2026) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-026-03574-z
Recent Advances in Nanotechnology for Targeted Protein Degradation
Xu, M., Yang, Y., Chen, J., Wang, X., Wang, S., Ma, F., & Shi, L. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c12624
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
BindingDB (2025) · UC San Diego · doi:10.7270/q2hh6qr8
BindingDB (2025) · UC San Diego · doi:10.7270/q2fj2nd5
BindingDB (2026) · UC San Diego · doi:10.7270/q2d223hr
BindingDB Entry 50018799: Medicinal chemistry strategies targeting PRMT5 for cancer therapy.
BindingDB (2024) · UC San Diego · doi:10.7270/q24x5d1g
BindingDB Entry 50018797: A bibliometric analysis of PROTAC from 2001 to 2021.
BindingDB (2024) · UC San Diego · doi:10.7270/q28p64s7
Metadata
- Authors
- Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J.
- Affiliations
- Sichuan University (CN)
- University of Tennessee Health Science Center (US)
- Chengdu Fifth People's Hospital (CN)
- Corresponding author
- Wang, Yuxi
- Zhang, Jifa
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-08-25
- Volume
- 65
- Issue
- 17
- Pages
- 11454-11477
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4293102944
- Cited by
- 100
- References
- 163
- Citations by year
- 2026: 16 · 2025: 34 · 2024: 28 · 2023: 20 · 2022: 2
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Science and Technology of the People's Republic of China (2018ZX09201018-021)
- Health Commission of Sichuan Province (21PJ149)
- Chinese Academy of Medical Sciences (2020-JKCS-014)
- Natural Science Foundation of Sichuan Province (2022NSFSC1365)
- Department of Science and Technology of Sichuan Province (2019YFS0003)
- National Natural Science Foundation of China (81903502, 82073318)
- Xinglin Foundation of Chengdu University (YYZX2021043)
- West China Hospital, Sichuan University (ZYGD20001)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- targeted protein degradation, neurodegenerative diseases, Alzheimer's disease, PROTACs, lysosome-targeting chimeras, undruggable proteins, amyloid-beta, protein degradation
- MeSH terms
- Chimera, Humans, Lysosomes, Proteins, Neurodegenerative Diseases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.